On May 22, 2020, Kintor Pharmaceutical Limited was successfully listed on the Main Board of the Hong Kong Stock Exchange with stock code of 9939.HK.
Huatai Financial acted as the Sole Sponsor, Joint Global Coordinator and Joint Bookrunner for the IPO transaction. Kintor Pharma is listed under Chapter 18A of the Listing Rules designated for the listing of pre-revenue biotech companies. It is the second IPO of Chapter 18A biotech companies in May 2020 in which Huatai Financial acted as sponsor, following Peijia Medical, demonstrating Huatai's expertise in serving innovative biotech companies and leading position in healthcare sector.
The IPO offering size was approximately HK$1,861 million, prior to the exercise of the over-allotment option. The Hong Kong retail tranche of the global offering was very significantly over-subscribed by approximately 550 times, making it one of the most popular offerings in 2020.
Founded in 2009, Kintor Pharma is a clinical-stage drug developer in China focused on the proprietary R&D of potential first-in-class and best-in-class drugs for cancers and other AR-related diseases. Its portfolio of drug candidates addresses major cancer types and other AR-related diseases with large market potential. The lead drug candidate, Proxalutamide, is a potential best-in-class drug undergoing phase III clinical trials in China and phase II clinical trials in the United States for mCRPC as well as clinical trials for breast cancer.